IPO
Filter News
Found 17,230 articles
-
Tandem Diabetes Care Announces First Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance
5/5/2021
Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, reported its financial results for the quarter ended March 31, 2021 and updated its sales guidance for the year ending December 31, 2021.
-
Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results
5/5/2021
"Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of HETLIOZ® in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda.
-
Cytokinetics to Hold Annual Meeting of Stockholders - May 05, 2021
5/5/2021
Cytokinetics, Incorporated announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021 at 10:30 AM Pacific Time at the Company’s headquarters, 280 East Grand Avenue, South San Francisco, CA.
-
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
5/5/2021
ATTACK Phase 3 topline data readout remains on track for second half of 2021
-
Interim report January - March 2021: Vicore Pharma Holding AB
5/5/2021
In February, Vicore completed a directed share issue raising 336 MSEK. The share issue was approved at an Extraordinary General Meeting in March.
-
MorphoSys AG Reports First Quarter 2021 Results
5/5/2021
For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
-
Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter
5/5/2021
Arena Pharmaceuticals, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2021.
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
5/5/2021
Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201
-
G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights
5/5/2021
Pivotal Phase 3 Trial of COSELA in Metastatic Triple-Negative Breast Cancer Underway to Evaluate the Survival Benefit of COSELA Compared with Placebo
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2021
5/5/2021
Blueprint Medicines Corporation announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 21,045 shares of its common stock and an aggregate of 10,520 restricted stock units to 13 new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Vapotherm Reports First Quarter 2021 Financial Results
5/5/2021
Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, announced first quarter 2021 financial results.
-
Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
5/5/2021
Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reported quarterly financial results for the first quarter period ended March 31, 2021, and provided a corporate overview and business update.
-
Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
5/5/2021
Net product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year
-
DLH Reports Fiscal 2021 Second Quarter ResultsRevenue Milestone of $61.5 Million; Operating Margins Expand; Enhanced Revenue Visibility from April CMOP Award
5/5/2021
DLH Holdings Corp., a leading provider of innovative healthcare services and solutions to federal agencies, announced financial results for its fiscal second quarter ended March 31, 2021.
-
OraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update
5/5/2021
First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 Million in Sales of Sample Collection Devices for COVID-19 Molecular Testing
-
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
5/5/2021
Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Classic Congenital Adrenal Hyperplasia
-
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
5/5/2021
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, provided a corporate update, and reported financial results for the three months ended March 31, 2021.
-
Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2021
5/5/2021
Fiscal fourth quarter 2021 revenue of $59.2 million, a 33% increase compared to fiscal fourth quarter 2020 revenue of $44.4 million
-
Axogen, Inc. Reports 2021 First Quarter Financial Results
5/5/2021
Axogen, Inc.Axogen, Inc.Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the first quarter ended March 31, 2021.
-
Addex Reports Q1 2021 Financial Results and Provides Corporate Update
5/5/2021
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the quarter ended March 31, 2021 and provided a corporate update.